
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 22, 2015

RELMADA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction
of incorporation)

333-184881

(Commission File Number)

45-5401931

(IRS Employer
Identification No.)

**757 Third Avenue, Suite 2018
New York, NY**

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code **(212) 376-5742**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Item 8.01. Other Events

On December 23, 2015, Relmada Therapeutics, Inc. (the “Company”) announced that, on December 22, 2015, the U.S. District Court for the District of Nevada (the “Court”) entered a preliminary injunction (the “Order”) to enjoin Laidlaw & Company (UK) Ltd. and its two principals, Matthew Eitner and James Ahern (collectively, the “Defendants”), from “continuing to disseminate false and misleading proxy materials.”

Under the terms of the Order, Defendants, among other things, “immediately must retract or correct its false and misleading proxy materials.” If Defendants choose to correct their false and misleading proxy materials, they must “disclose that they missed the advance notice deadline for stockholders to validly nominate Relmada directors at the 2015 annual meeting,” “disclose that there are only two seats up for election on Relmada’s Board at the 2015 annual meeting,” “disclose that the Board of Directors has the sole authority to set the size of the Board,” and “disclose that the corporate actions taken by Relmada’s current Board and stockholders that Defendants’ label as ‘entrenchment’ all were authorized under Relmada’s articles of incorporation, bylaws, and Nevada law.”

The Company previously filed a lawsuit with the Court on December 9, 2015 alleging, among other things, that the press release issued by Defendants on December 4, 2015, which was subsequently filed with the Securities and Exchange Commission (“SEC”) on Schedule 14A, contains material misrepresentations and omissions in violation of federal securities law. In addition to violating Rule 14a-9 of the Securities Exchange Act of 1934, which provides that no solicitation of stockholders may be made any false or misleading statement, the lawsuit argues that the Laidlaw solicitation materials also conflict with Relmada’s Articles of Incorporation and Bylaws, as well as Nevada law. Under the lawsuit, on December 10, 2015, the Court issued a temporary restraining order that, among other things, enjoined Defendants from disseminating false and misleading information in direct violation of federal securities laws, including applicable proxy laws. The Order continues in place the restrictions contained in the temporary restraining order.

The Order will remain in place pending a full trial on the merits.

These matters were announced in a press release issued December 23, 2015, which is attached hereto as Exhibit 99.1. The Order is attached hereto as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release
99.2	Preliminary Injunction

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 23, 2015

RELMADA THERAPEUTICS, INC.

By: /s/ Sergio Traversa

Name: Sergio Traversa

Title: Chief Executive Officer



U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern

Relmada Therapeutics Victorious in Obtaining Preliminary Injunction to Prevent Laidlaw's Continued Dissemination of False and Misleading Statements

NEW YORK, Dec. 23, 2015 -- Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced that following a hearing, the U.S. District Court for the District of Nevada granted Relmada's request and granted a Preliminary Injunction against Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern. The Court Order enjoins Laidlaw and Messrs. Eitner and Ahern from "continuing to disseminate false and misleading proxy materials."

As previously announced, the Court first issued a temporary restraining order and an associated injunction against Laidlaw and Messrs. Eitner and Ahern on December 10, 2015. The Court Order issued follows the previously announced lawsuit that Relmada filed against Laidlaw and Messrs. Eitner and Ahern as a result of their dissemination of materially false and misleading information in Laidlaw's attempt to take effective control of Relmada.

"We are pleased that the Court has again granted an injunction and prevented Laidlaw from disseminating its false and misleading proxy materials," said Sergio Traversa, Chief Executive Officer of Relmada. "The Relmada Board has acted, and will continue to act, in the best interests of Relmada and all of its stockholders. In contrast, the actions of Laidlaw and its principals make clear to us that their interests are very different from all other Relmada stockholders."

The Relmada Board of Directors and management team have built a robust product portfolio with a multi-pronged development plan that is delivering results – with significant value creation opportunities possible in the next 12 to 24 months. For example, Relmada recently reported positive study results for BuTab for the treatment of both chronic pain and opioid dependence indications, which represents a multi-billion dollar market opportunity, as well as the successful completion of its multiple ascending dose study with d-Methadone for neuropathic pain. Relmada's highly qualified Board has the experience necessary to continue this positive momentum and is committed to serving the interests of Relmada and ALL of its stockholders.

Time is short. The 2015 Annual Meeting of Relmada Stockholders will be held on December 30, 2015. Relmada urges stockholders to follow the unanimous recommendation of the Relmada Board and vote "FOR" Relmada's director nominees – Shreeram Agharkar and Maged Shenouda – on the WHITE proxy card today.

Relmada Therapeutics
W: www.relmada.com | E: info@relmada.com



The Court Order will be made available on Form 8-K, which will be filed with the Securities and Exchange Commission.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Important Stockholder Information

The Company will hold its 2015 Annual Meeting of Stockholders on December 30, 2015. On November 27, 2015, the Company filed with the U.S. Securities and Exchange Commission (the "SEC") and mailed to its stockholders a definitive proxy statement in connection with the Annual Meeting and the solicitation of proxies (the "2015 Proxy Statement"). The 2015 Proxy Statement contains important information about Relmada, the Annual Meeting and related matters.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE 2015 PROXY STATEMENT AND ANY OTHER RELEVANT SOLICITATION MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION.

The 2015 Proxy Statement and other relevant solicitation materials (when they become available), and any and all documents filed by the Company with the SEC, may be obtained by investors and security holders free of charge at the SEC's web site at www.sec.gov. In addition, Relmada's filings with the SEC, including the 2015 Proxy Statement and other relevant solicitation materials (when they become available), may be obtained, without charge, from Relmada by directing a request to the Company at 757 3rd Avenue, Suite 2018, New York, New York 10017, Attention: Senior Vice President Finance and Corporate Development. Such materials are also available at ir.relmada.com/all-sec-filings.

Relmada and its directors, officers and employees are deemed to be participants in the solicitation of proxies from Relmada's stockholders in connection with the Annual Meeting. Information regarding Relmada's directors and executive officers, including a description of their direct and indirect interests by security holdings, is contained in the 2015 Proxy Statement and in Relmada's 2015 Annual Report on Form 10-K filed with the SEC on September 11, 2015 (the "2015 Annual Report").

Relmada Therapeutics
W: www.relmada.com | E: info@relmada.com

**Forward-Looking Statements**

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Contacts**Investors:**

Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
(212) 376-5776
mbecker@relmada.com

Jonathan Salzberger / Scott Winter
Innisfree M&A Incorporated
(212) 750-5833

Media:

Barrett Golden / Nicholas Lamplough
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Relmada Therapeutics
W: www.relmada.com | E: info@relmada.com

BROWNSTEIN HYATT FARBER SCHRECK, LLP

100 North City parkway, Suite 1600
Las Vegas, NV 89106
(702) 382-2101

JEFFREY S. RUGG, ESQ., Bar # 10978
jrugg@BHFS.com
BROWNSTEIN HYATT FARBER SCHRECK, LLP
100 North City Parkway, Suite 1600
Las Vegas, Nevada 89106
Telephone: 702.382.2101
Facsimile: 702.382.8135

DEBORAH S. BIRNBACH, ESQ. (*pro hac vice*)
dbirnbach@goodwinprocter.com
ADAM SLUTSKY, ESQ. (*pro hac vice*)
aslutsky@goodwinprocter.com
GOODWIN PROCTER LLP
Exchange Place
Boston, MA 02109
Tel: 617.570.1000
Facsimile: 617.523.1231

Attorneys for Plaintiff Relmada Therapeutics, Inc.

UNITED STATES DISTRICT COURT

DISTRICT OF NEVADA

RELmada THERAPEUTICS, INC., a Nevada corporation,

Plaintiff,

v.

LIDLAW & COMPANY (UK) LTD., a foreign corporation,
MATTHEW D. EITNER, an individual and citizen of New Jersey,
and **JAMES P. AHERN**, an individual and citizen of New Jersey,

Defendants.

Case No.: 15-cv-2338-JCM-CWH

INJUNCTION **PRELIMINARY**

UPON CONSIDERATION of the Motion for Preliminary Injunction filed by Plaintiff Relmada Therapeutics, Inc. (“Relmada”) for a preliminary injunction against Defendants Laidlaw & Company (UK) Ltd., Matthew D. Eitner, and James P. Ahern (collectively, “Defendants”), the Federal Rules of Civil Procedure, the pleadings and papers on file herein, the Memorandum of Points and Authorities, including the Declaration of Sergio Traversa, together with the exhibits, and for good cause shown:

THE COURT HEREBY FINDS THAT,

1. Relmada is likely to succeed on the merits because the False Solicitation contains material misstatements and omissions;

BROWNSTEIN HYATT FARBER SCHRECK, LLP

100 North City parkway, Suite 1600
Las Vegas, NV 89106
(702) 382-2101

2. Relmada and its stockholders will suffer irreparable harm if Defendants are not enjoined from continuing to disseminate false and misleading proxy materials and required to retract or correct those materials;

3. The balance of hardships favors the issuance of an injunction here because the right of Relmada's stockholders to vote for qualified directors will be directly impacted, and an improper vote will hold up the election of qualified directors resulting in uncertainty over the corporate governance of the Company; and

4. The public interest will benefit from granting an injunction because it prevents an uninformed shareholder vote.

THEREFORE, IT IS HEREBY ORDERED THAT, pending a full trial on the merits:

1. Defendants shall be enjoined from continuing to disseminate false and misleading proxy materials.

2. Defendants immediately must retract or correct their false and misleading proxy materials.

3. If Defendants choose to correct their false and misleading proxy materials, they immediately shall:

(a) Disclose that they missed the advance notice deadline for stockholders to validly nominate Relmada directors at the 2015 annual meeting;

(b) Disclose that there are only two seats up for election on Relmada's Board at the 2015 annual meeting;


(c) Disclose that the Board of Directors has the sole authority to set the size of the Board; and

(d) Disclose that the corporate actions taken by Relmada's current Board and stockholders that Defendants' label as "entrenchment" all were authorized under Relmada's articles of incorporation, bylaws, and Nevada law.

BROWNSTEIN HYATT FARBER SCHRECK, LLP

100 North City parkway, Suite 1600
Las Vegas, NV 89106
(702) 382-2101

ENTERED December 22, 2015.



UNITED STATES DISTRICT JUDGE

Respectfully Submitted By:

BROWNSTEIN HYATT FARBER SCHRECK, LLP

By: /s/ Jeffrey S. Rugg

JEFFREY S. RUGG, ESQ., Bar # 10978

jrugg@bhfs.com

100 North City Parkway, Suite 1600

Las Vegas, Nevada 89106

Telephone: 702.382.2101

Facsimile: 702.382.8135

DEBORAH S. BIRNBACH, ESQ. (*pro hac vice*)

dbirnbach@goodwinprocter.com

ADAM SLUTSKY, ESQ. (*pro hac vice*)

aslutsky@goodwinprocter.com

GOODWIN PROCTER LLP

Exchange Place

Boston, MA 02109

Tel: 617.570.1000

Facsimile: 617.523.1231

Attorneys for Plaintiff Relmada Therapeutics, Inc.